Friday, September 23, 2016

Carnitor


See also: Generic Carnitor SF


Carnitor is a brand name of levocarnitine, approved by the FDA in the following formulation(s):


CARNITOR (levocarnitine - injectable; injection)



  • Manufacturer: SIGMA TAU

    Approval date: December 16, 1992

    Strength(s): 200MG/ML [RLD][AP]

CARNITOR (levocarnitine - solution; oral)



  • Manufacturer: SIGMA TAU

    Approval date: April 10, 1986

    Strength(s): 1GM/10ML [RLD][AA]

CARNITOR (levocarnitine - tablet; oral)



  • Manufacturer: SIGMA TAU

    Approval date: December 27, 1985

    Strength(s): 330MG [RLD][AB]

Has a generic version of Carnitor been approved?


A generic version of Carnitor has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Carnitor and have been approved by the FDA:


levocarnitine injectable; injection



  • Manufacturer: BEDFORD

    Approval date: March 29, 2001

    Strength(s): 200MG/ML [AP]


  • Manufacturer: LUITPOLD

    Approval date: June 22, 2001

    Strength(s): 200MG/ML [AP]


  • Manufacturer: TEVA PARENTERAL

    Approval date: March 29, 2001

    Strength(s): 200MG/ML [AP]

levocarnitine solution; oral



  • Manufacturer: HI TECH PHARMA

    Approval date: October 25, 2007

    Strength(s): 1GM/10ML [AA]


  • Manufacturer: LYNE

    Approval date: August 10, 2004

    Strength(s): 1GM/10ML [AA]

levocarnitine tablet; oral



  • Manufacturer: COREPHARMA

    Approval date: September 20, 2004

    Strength(s): 330MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Carnitor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Treating chronic uremic patients undergoing periodical dialysis
    Patent 6,335,369
    Issued: January 1, 2002
    Inventor(s): Claudio; Cavazza
    Assignee(s): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Chronic uremic patients undergoing periodical dialysis are treated with carnitine or one of its salts to prevent or treat carnitine deficiency in patients with end stage renal disease. An effective dose of carnitine, preferably L-carnitine fumarate, is administered preferably intravenously into the venous return line after each dialysis session.
    Patent expiration dates:

    • January 18, 2021
      ✓ 
      Patent use: USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS




  • Treating chronic uremic patients undergoing periodical dialysis
    Patent 6,429,230
    Issued: August 6, 2002
    Inventor(s): Claudio; Cavazza
    Assignee(s): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    The method for the treatment chronic uremic patients undergoing periodical dialysis is useful for preventing and/or treating carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. The method according to the present invention comprises administering an effective dose of carnitine intravenously into the venous return line after each dialysis session.
    Patent expiration dates:

    • January 18, 2021
      ✓ 
      Patent use: USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS




  • Treating chronic uremic patients undergoing periodic dialysis
    Patent 6,696,493
    Issued: February 24, 2004
    Inventor(s): Claudio; Cavazza
    Assignee(s): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    The method for the treatment of chronic uremic patients undergoing periodical dialysis is useful for preventing and/or treating carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. The method according to the present invention comprises administering an effective dose of carnitine intravenously into the venous return line after each dialysis session.
    Patent expiration dates:

    • January 18, 2021
      ✓ 
      Patent use: USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS



See also...

  • Carnitor Consumer Information (Wolters Kluwer)
  • Carnitor Solution Consumer Information (Wolters Kluwer)
  • Carnitor Advanced Consumer Information (Micromedex)
  • Carnitor AHFS DI Monographs (ASHP)
  • Levocarnitine Consumer Information (Wolters Kluwer)
  • Levocarnitine Solution Consumer Information (Wolters Kluwer)
  • Levocarnitine Oral, Intravenous Advanced Consumer Information (Micromedex)
  • Levocarnitine AHFS DI Monographs (ASHP)
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)